1-叔丁基-3-环己基脲 | 54088-56-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 1-叔丁基-3-环己基脲
• 英文名称: N-Cyclohexyl-N'-t-butylharnstoff
• 英文别名: N-tert-Butyl-N'-cyclohexyl-harnstoff；N-(tert-butyl)-N'-cyclohexylurea；1-tert-butyl-3-cyclohexylurea
• CAS: 54088-56-1
• 化学式: C₁₁H₂₂N₂O
• mdl: MFCD00029410
• 分子量: 198.308
• InChiKey: COLUTWBYJCLQKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  1-叔丁基-3-环己基脲 在 sodium tetrahydroborate 作用下， 以 吡啶 为溶剂， 生成 N¹--N²-cyclohexyl-formamidin
  参考文献：
  名称：

  吡啶中取代脲与硼氢化钠的反应

  摘要：

  DOI：

  10.1016/s0040-4039(01)87786-8
• 作为产物：
  描述：

  t-butylcyclohexylcarbodiimide 在 盐酸 作用下， 生成 1-叔丁基-3-环己基脲
  参考文献：
  名称：

  437.乙酰乙酸的衍生物。第九部分 二烯与碳二亚胺的反应

  摘要：

  DOI：

  10.1039/jr9580002134

文献信息

• Iron(iii) catalysed synthesis of unsymmetrical di and trisubstituted ureas – a variation of classical Ritter reaction
  作者：Hosamani Basavaprabhu、Vommina V. Sureshbabu

  DOI：10.1039/c2ob06916d

  日期：——

  An application of the classical Ritter reaction for the synthesis of unsymmetrical di and trisubstituted ureas catalyzed by FeCl3 is described. The protocol is of significant interest in view of the easy availability of precursors, mild reaction conditions employed and interestingly its applicability for the alkylation of alcohols capable of forming stable carbocationic intermediates even to the sterically hindered moieties.

  介绍了利用经典Ritter反应合成非对称二取代和三取代脲类化合物的方法，该反应由FeCl3催化。该方案具有重要意义，因为其前体易于获得，反应条件温和，而且在对能够形成稳定碳正离子中间体的醇进行烷基化时，即使是空间位阻较大的基团也能适用。
• An easy access to unsymmetrical ureas: a photocatalytic approach to the Lossen rearrangement
  作者：Arvind K. Yadav、Vishnu P. Srivastava、Lal Dhar S. Yadav

  DOI：10.1039/c4ra03805c

  日期：——

  synthesis of unsymmetrical ureas from various hydroxamic acids and amines has been developed. Plausibly, the protocol involves visible-light-initiated in situ formation of Vilsmeier–Haack reagent and COBr2 with CBr4 and a catalytic amount of DMF in the presence of Ru(bpy)3Cl2 as a photocatalyst to bring about the Lossen rearrangement at room temperature.

  已经开发了一种由各种异羟肟酸和胺合成不对称脲的有效且操作简单的方法。可能地，该协议涉及可见光引发的原位形成Vilsmeier-Haack试剂和带有CBr 4的COBr 2以及在Ru（bpy）3 Cl 2作为光催化剂的情况下催化量的DMF，以引起Lossen重排。在室温下。
• INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
  申请人：Claridge Stephen William

  公开号：US20090264440A1

  公开（公告）日：2009-10-22

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，本发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号和HGF受体信号的传导。更具体地，本发明涉及抑制VEGF受体信号和HGF受体信号的化合物、组合物和方法。本发明还提供了治疗细胞增殖性疾病和状况的组合物和方法。
• Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
  申请人：Nakajima Suanne

  公开号：US20070060510A1

  公开（公告）日：2007-03-15

  The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及公式I或II的化合物，或其药学上可接受的盐、酯或前药，其抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶NS3-NS4A的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗丙型肝炎病毒感染的患者。本发明还涉及通过给予本发明化合物的制药组合物来治疗患有丙型肝炎病毒感染的患者的方法。
• Processes and intermediates for preparing fused heterocyclic kinase inhibitors
  申请人：Raeppel Franck

  公开号：US20090286984A1

  公开（公告）日：2009-11-19

  This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

  本发明涉及用于制造融合杂环型激酶抑制剂化合物的过程和中间体，例如噻吩并吡啶基化合物，并涉及用于制备在制造融合杂环型激酶抑制剂化合物，例如噻吩并吡啶基化合物中有用的中间体的过程和中间体，特别是在工业水平上。